MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management, including Leland Wilson, Chief Executive Officer; Timothy Morris, Chief Financial Officer, and Wesley W. Day, Ph.D., Vice President, Clinical Development, will participate in three investment conferences during the month of September.
The conference presentation schedule is as follows:
Stifel Nicolaus 2011 Healthcare Conference
Wednesday, September 7, 2011
8:00 a.m. ET
Four Seasons Hotel Boston
UBS Global Life Sciences Conference
Tuesday, September 20, 2011
2:00 p.m. ET
Grand Hyatt New York
New York, NY
Sixth Annual JMP Securities Healthcare Conference
Wednesday, September 28, 2011
12:00 p.m. ET
St. Regis New York
New York, NY
A live audio webcast and an archive of the presentations will be available at http://ir.vivus.com.
About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.CONTACT: VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved